Insider Buying: Orthocell (ASX:OCC) Insider Acquires A$25,025.40 in Stock

Orthocell Limited (ASX:OCC) insider Michael McNulty acquired 26,041 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were acquired at an average cost of A$0.96 per share, with a total value of A$25,025.40.

Orthocell Price Performance

The company has a market capitalization of $202.09 million, a P/E ratio of -17.90 and a beta of 1.16. The company has a debt-to-equity ratio of 2.03, a current ratio of 9.17 and a quick ratio of 5.07.

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair.